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Abstract
Allergic airways disease is a consequence of a Th2 response to an allergen leading to a series of manifestations such as
production of allergen-specific IgE, inflammatory infiltrates in the airways, and airway hyper-reactivity (AHR). Several
strategies have been reported for tolerance induction to allergens leading to protection from allergic airways disease. We
now show that CD4 blockade at the time of house dust mite sensitization induces antigen-specific tolerance in mice.
Tolerance induction is robust enough to be effective in pre-sensitized animals, even in those where AHR was pre-
established. Tolerant mice are protected from airways eosinophilia, Th2 lung infiltration, and AHR. Furthermore, anti-CD4
treated mice remain immune competent to mount immune responses, including Th2, to unrelated antigens. Our findings,
therefore, describe a strategy for tolerance induction potentially applicable to other immunogenic proteins besides
allergens.
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Introduction
The control of deleterious immune responses causing diseases,
such as allergy, autoimmunity and transplant rejection, has been
one of the main objectives of immunologists. Moreover, the global
prevalence of this type of diseases has been steadily increasing.
Several strategies have been recently described to induce
tolerance to allergens thus preventing allergic airways disease
[1,2,3,4]. In brief, they can rely on the induction of dendritic cell
(DC) populations or regulatory T cells (Treg) able to control
pathologic T cell clones, in a process where IL-10 and TGF-b can
participate [1,5,6,7,8,9,10]. In addition, disease prevention may be
achieved by skewing the immune response from a Th2 to a Th1
phenotype [11].
In fact, the realization of the critical importance of T cells in the
pathogenesis of allergic airways disease was well demonstrated by
studies where anti-CD4 monoclonal antibodies (MAbs) causing the
depletion of this T cell subset could prevent the disease in mice
[12]. Such pre-clinical studies with CD4 T cell depletion provided
the rationale for clinical trials with depleting anti-CD4 MAbs
where the short-term benefit observed was probably associated
with transient immune suppression [13]. As a consequence, the
interest has shifted towards MAbs capable of blocking molecular
interactions but without leading to direct cell lysis.
Some reports have shown prevention of allergic airways disease
following the blockade of T cell co-stimulatory or co-receptor
molecules with non-depleting MAbs, but it remains unclear
whether long-term antigen-specific tolerance is achieved or what
are the mechanisms involved [14,15,16,17]. We now describe
CD4 blockade at the time of exposure with a model antigen,
ovalbumin (OVA), or a clinically relevant allergen, house dust mite
(HDM), can induce antigen-specific tolerance and protection from
allergic airways disease. The mechanism leading to antigen-
specific tolerance without affecting protective immune responses
(including Th2-type responses) to additional antigens is indepen-
dent of a switch between a Th2-type and Th1-type immune
response. Since CD4 blockade is achieved with a non-depleting
MAb, T cells not activated by the antigen remain unaffected to
mount protective immune responses towards unrelated antigens at
a later time.
Tolerance induction by CD4 blockade is robust enough to be
effective in pre-sensitized animals and even in animals where AHR
was previously established. The tolerant mice show protection
from allergic manifestations elicited by intranasal exposure to the
antigen: they do not develop airways eosinophilia, goblet cell
hyperplasia, production of Th2 cytokines in the lung, production
of antigen-specific IgE or IgG1, and, importantly, do not develop
airway hyperreactivity (AHR) in response to inhaled methacholine
(MCh).
Results
Co-receptor blockade with non-depleting anti-CD4 MAb
prevents allergic sensitization in mice
Using a well established murine model of allergic airways
disease we sought to determine if non-depleting MAbs targeting
the T cell co-receptor molecule CD4 were effective in preventing
allergic sensitization with HDM or a model antigen (OVA).
BALB/c mice were sensitized with two i.p. injections of OVA-
alum or HDM-alum on days 1 and 14, and challenged with 50 mg
OVAorHDM i.n.on days20, 21 and 22(Figure1A). Experimental
groupsweretreated with 1 mgi.p.ofanti-CD4 oran isotype control
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6on the days before and after each immunization, and sacrificed
24 hours following the last intranasal challenge.
Mice treated with anti-CD4 had a marked reduction in BAL
eosinophils when compared with sensitized animals, to levels
similar to naı ¨ve animals or animals sensitized in the absence of the
antigen (Figure 1B, and Figure S1). The absence of goblet cell
hyperplasia and inflammatory infiltrate in the airways of anti-CD4
treated mice was confirmed by histology (Figure 1C). Further-
more, anti-CD4 treatment prevented effective generation of Th2-
driven OVA- and HDM-specific IgG1 and IgE (Figure 1D). We
could not detect Th1-driven antigen-specific IgG2a in any animal
(not shown). Animals treated with anti-CD4 showed a marked
reduction of IL-4 and IL-5 in lung homogenates to levels similar to
naive animals (Figure 1E). Importantly, we found no evidence for
Th1 or Th17 deviation (as inferred by levels of IFNc or IL-17), nor
increased levels of the immune-regulatory cytokine IL-10 (not
shown). Cytokines in BAL were similar to lung homogenates (not
shown).
Figure 1. Prevention of allergic sensitization with anti-CD4 MAb. (A) Female BALB/c mice were sensitized with 20 mg OVA-alum or 50 mg
HDM-Alum i.p. and challenged with 50 mg OVA or HDM in saline i.n. on the indicated days. Some animals were treated with 1 mg anti-CD4 or an
isotype control i.p. as shown. Naive mice, not subjected to any intervention, were also studied as a control group. (B) Cellular composition of the BAL.
Animals treated with anti-CD4 have less eosinophils in the BAL (n=6, *** P,0.001). (C) Histological sections of lung tissue were stained with
hematoxilin/eosin and PAS (inset). Anti-CD4-treated mice have reduced inflammatory infiltrate and goblet cell hyperplasia, to levels similar to naive
controls. Bars represent 10 mm (2.5 mm in the inset). (D) Quantification of serum OVA- and HDM-specific IgG1 and IgE. Anti-CD4 MAb treated mice
show a significant reduction of the Th2-driven immunoglobulins (n=6, *** P,0.001 and ** P,0.01 as indicated). (E) The Th2 cytokines IL-4 and IL-5
were down to basal levels in lung homogenates of anti-CD4 treated mice (n=6, * P,0.05 and *** P,0.001). (F) Invasive measurement of respiratory
mechanics shows that animals treated with anti-CD4 MAbs had reduced airway resistance to increasing doses of inhaled MCh, when compared with
sensitized control animals (n=8). Data (B–F) are representative of at least three independent experiments.
doi:10.1371/journal.pone.0022320.g001
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AHR in response to increasing doses of inhaled MCh. Our data
show that anti-CD4 treatment prevented AHR (Figure 1F and
Figure S2).
The tolerance state is maintained following clearance of
the MAb
We then studied whether tolerance induction with non-
depleting anti-CD4 would protect the animals from subsequent
exposure to the same antigens, at a time the therapeutic MAb had
been cleared. For this purpose treated mice with anti-CD4 at the
time of initial sensitization with OVA or HDM, and the same mice
were again immunized with the same antigens 50 days following
the initial treatment (Figure 2A).
Sensitization with OVA-alum or HDM-alum did not lead to
airways eosinophilia in mice previously exposed to the same
antigens under the cover of non-depleting anti-CD4 (Figure 2B
and Figure S1). Furthermore, the treated mice also failed to
produce antigen-specific IgG1 and IgE to OVA-alum and HDM-
alum (Figure 2C). And importantly, AHR to increased concen-
trations of inhaled MCh was also absent in anti-CD4 treated mice
(Figure 2D and Figure S2).
We could therefore conclude that a short course of anti-CD4
was leading to long-term effects. Although the MAb we used (clone
YTS177) is known to have a non-depleting isotype [18], and we
confirmed anti-CD4 treatment was not directly leading to T cell
lysis (not shown), we had to confirm the treated mice remained
immune competent.
Tolerant mice remain immunocompetent
In order to study the antigen-specificity of tolerance induction,
we used a second unrelated antigen: b-lactoglobulin (b-LG). We
compared immune responses to OVA and b-LG, since these are
two defined antigens with similar characteristics, while HDM is a
complex protein extract containing many distinct antigens.
BALB/c mice were treated with non-depleting anti-CD4 MAb
together with OVA-alum (tOVA) or b-LG-alum (tb-LG) in order
to establish immune tolerance to those antigens (Figure 3A). At
day 50 the animals were immunized with the same antigen used at
the time of tolerization (day 0) or with the second unrelated
antigen. All mice were subsequently challenged i.n. with the same
antigen used at day 50. All animals remained protected from
mounting airways inflammation in response to the antigen used for
tolerization, but fully competent to undergo a Th2 response to the
second antigen leading to airways eosinophilia, production of IgE
and IgG1, and AHR (Figure 3B–D and Figure S2). These results
suggest that CD4-blockade affects specifically the T cells that are
being activated at the time of treatment, and sparing non-activated
cells, thus leading to antigen specific tolerance where immune
responses against different antigens are not suppressed.
Tolerance can be achieved in sensitized mice
To assess whether tolerance can be induced in pre-sensitized
mice, BALB/c mice sensitized with OVA or HDM were treated
with the same antigen under the cover of anti-CD4 50 days
following initial sensitization (Figure 4A). For consistency with
previous experiments we maintained the tolerance-inducing
regime as two administrations of antigen-alum+anti-CD4 two
weeks apart.
We found, both OVA- and HDM-sensitized mice treated with
anti-CD4 were prevented from AHR, maintaining normal airway
response to increased concentrations of inhaled MCh (Figure 4B
and Figure S2). We confirmed the efficient sensitization of all
groups of immunized animals by the presence of antigen-specific
IgG1 and IgE antibodies in sera (not shown), although the mice
had not been exposed to prior airway inflammation. As a
consequence, the protection from AHR is effective in spite of
high titres of antigen-specific immunoglobulins – possibly
representing an impact on the late-phase response, and dissoci-
ation between high IgE and AHR.
We then assessed whether tolerance induction in pre-sensitized
mice remained antigen-specific. BALB/c mice sensitized with
OVA-alum or b-LG-alum were treated with anti-CD4 MAb, 50
days following the initial intervention, in the presence of either the
initial (OVA or b-LG) or a different antigen (b-LG or OVA,
respectively; Figure 4C). Sensitized mice were protected from
airway eosinophilia when treated with anti-CD4 in the presence of
the same antigen used for sensitization (OVA .tOVA and b-LG
.tb-LG, Figure 4D). The protective effect was, therefore, not due
to the persistence of the therapeutic antibody in circulation at the
time of intranasal exposure to the antigen since mice immunized
with a different antigens not present during anti-CD4 treatment
(and therefore with equivalent doses of circulating anti-CD4 at the
time of challenge) were not protected (OVA .tb-LG and b-LG
.tOVA). The observation that animals receiving the antibody
treatment together with a different antigen than used for
immunization develop inflammatory changes similar to untreated
control animals, or animals exposed to alum in the absence of the
antigen (Figure S1), are consistent with the antigen-specificity of
the tolerance state described above.
Mice exposed to allergic airways disease can be
protected from AHR following anti-CD4 treatment
However, it is understood that the onset of inflammation in the
airways becomes a significant hurdle for immune modulation
leading to tolerance. Therefore, we investigated whether mice
sensitized to OVA or HDM and exposed to the antigen i.n. could
benefit from subsequent anti-CD4 treatment (Figure 5A). A single
i.n. challenge with antigen in sensitized mice was sufficient to
induce AHR (Figure S3).
We found that administration of HDM under the cover of non-
depleting anti-CD4 30 days following induction of allergic airways
disease was effective in preventing AHR following subsequent
challenge with the same antigen (Figure 5B). We repeated the
same studies with OVA with similar results (Figure 5B and Figure
S2).
Discussion
Our data shows that CD4 blockade is effective in inducing
antigen-specific tolerance to a clinically relevant allergen (HDM),
thus preventing the manifestations of allergic airways disease
following intranasal allergen challenge: Th2 and eosinophilic
infiltrate of the airways, goblet cell hyperplasia, and AHR. The
tolerogenic treatment is not only effective in preventing the disease
in naive animals, but also confers considerable protection to mice
previously sensitized with the allergen. Although in different
experiments we tested mice with different ages, we could not find
an age-related difference in their response to induction of allergic
airways disease (Figure S4).
It should be noted that the use of tolerogenic MAbs in
transplantation, with the same objective of preventing an
inflammatory response to non-self antigens, have resulted in a
different outcome from what we have observed. In transplanta-
tion, tolerance induction in sensitized animals has been difficult to
achieve, except when both anti-CD4 and anti-CD8 MAbs are
combined [19], with anti-CD8 MAbs probably required to control
Tolerance Induction to House Dust Mite
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CD40L has also been reported as less effective than anti-CD4,
requiring depletion of CD8
+ T cells even in non-sensitized animals
[20,21]. The obstacle created by sensitization in relation to
tolerance induction is also evidenced by reports showing that
heterologous immunity reduces the effectiveness of tolerogenic
protocols in transplantation [22]. Our data shows that the anti-
CD4 antibody treatment can also be beneficial to already
sensitized animals. This may be due to the fact that the T effector
cell frequency is significantly lower for allergens than for
alloantigens and that the response to allergens is predominantly
restricted to the CD4
+ compartment. It is likely that such different
outcome observed in transplantation versus allergy may be due to
the induction of different tolerogenic mechanisms. In fact our
preliminary data suggests that Foxp3
+ Treg cells may play a more
important role in transplantation tolerance than in tolerance
induced to allergens – something that still requires further
elucidation.
Our data also suggests it is likely that in sensitized mice the
antibody treatment has an impact exclusively on the late response
(mediated by Th2 and NKT cells), without preventing the early
response mediated by mast cell degranulation in response to their
surface IgE cross-linking, as the allergen-specific IgG1 and IgE
titres remain high in treated mice. But even without targeting early
mast cell degranulation, the MAb treatment is likely to lead to a
putative long-term benefit given the importance of the Th2-
mediated response for the persistence of the inflammatory changes
associated with airways remodeling and chronic manifestations of
the disease [4]. This issue will require confirmation in chronic
models of disease.
The antigen-specificity of Treg cell-mediated tolerance has been
a controversial issue [23,24]. We show that effective tolerance
induction requires the presence of the appropriate antigen at the
time of CD4 blockade leading to antigen-specific tolerance. In
these experiments we waited 50 days following initial sensitization
to minimize the amount of antigen still present in the animal at the
time of the tolerogenic treatment. These data also established that
MAbs administered at day 50 (Figure 3) were not contributing
significantly to the prevention of the disease by being in circulation
at the time of intranasal challenge, since no beneficial effect is
observed in animals treated with the same antibody dose together
with an irrelevant antigen. Importantly, most previous studies
addressing the putative tolerance-inducing potential of monoclo-
nal antibodies, namely anti-CD4 [15], did not address the antigen-
specificity of the phenomenon or the immune competence of
treated mice.
Several MAbs have been recently used as immune modulators
in a wide range of diseases, including allergy [25]. Anti-CD4
MAbs have been evaluated both in pre-clinical non-human
primate models of transplantation and autoimmunity, as well as
in clinical studies [13,26,27]. Their therapeutic effectiveness was
modest, short-term, and likely to be a consequence of transient
immunosuppression and not tolerance. With hindsight those
unimpressive results are not surprising due to technical details
related with dosing and the MAb characteristics. The clinical trials
have used mouse or chimeric MAb that elicited immune responses
leading to their rapid clearance [28]. In addition, most of those
studies, including a clinical trial in human asthma (with the
depleting anti-CD4 MAb keliximab) [13], did not take advantage
of non-depleting anti-CD4 MAbs. Therefore, and as a conse-
quence of the adverse side effects associated with depleting
reagents, it was not possible to attain a neutralizing dose of anti-
CD4 know to be the most effective for tolerance induction. At this
time, particularly given the promising results with non-depleting
anti-CD3 in early onset diabetes patients [29], the past experience
of anti-CD4 in human patients should be reassessed in face of
Figure 3. Mice treated with anti-CD4 are competent to respond to unrelated antigens. (A) Mice initially tolerized to OVA or b-LG (as
described in previous figures) were sensitized i.p. with a different antigen at days 50 and 64, and challenged i.n. with the same antigen used at day 50.
(B) Only animals tolerized to the same antigen used for sensitization at day 50 were protected from BAL eosinophilia (n=6, *** P,0.001).
(C) Tolerance induction to OVA did not prevent subsequent production of b-LG-driven IgE or IgG1, conversely, tolerance to b-LG did not hamper the
generation of OVA-specific IgG1 or IgE (n=6, *** P,0.001). (D) AHR in response to MCh was observed in animals tolerized to an antigen different
from the one used for subsequent sensitization (tOVA .b-LG and tb-LG .OVA) (n=8, * P,0.05 at 10 mg/ml MCh). Data are representative of two
independent experiments.
doi:10.1371/journal.pone.0022320.g003
Figure 2. Tolerized mice resist subsequent sensitization and challenge. (A) BALB/c mice were initially sensitized with OVA or HDM under the
cover of anti-CD4 as described in Figure 1. Those mice were sensitized with the same antigens on days 50 and 64, and subsequently challenged i.n.
(B) Animals trated with anti-CD4 were protected from BAL eosinophilia (n=6, ** P,0.01 for OVA; * P,0.05 for HDM). (C) CD4-blockade prevented
production of IgG1 and IgE in subsequent sensitizations (n=6, *** P,0.001 and ** P,0.01 as indicated). (D) Tolerance to OVA or HDM prevented AHR
to inhaled MCh (n=6). Data are representative of three independent experiments.
doi:10.1371/journal.pone.0022320.g002
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immunogenic humanized anti-CD4 MAb has been recently
engineered, and its safety evaluated in human volunteers [30].
Our results suggest the specific targeting of CD4 T cells in
allergic airways disease can have a potent effect in achieving long-
term protection from subsequent inflammatory changes induced
Figure 5. Protection from AHR in animals previously exposed to airways inflammation. (A) Balb/c mice sensitized and challenged i.n. with
HDM-alum or OVA-alum were tolerized to the same antigens on days 50 and 64, and challenged i.n. with the same antigens. (B) The animals treated
with HDM or OVA under the cover of anti-CD4 were protected from AHR in response to inhaled MCh (n=6, ** P,0.01 or *** P,0.001 as indicated).
Data are representative of two independent experiments.
doi:10.1371/journal.pone.0022320.g005
Figure 4. Tolerogenic effect of anti-CD4 treatment is antigen-specific and effective in sensitized animals. (A) BALB/c mice sensitized
with OVA-alum or HDM-alum were tolerized to the same antigens on days 50 and 64, and challenged i.n. with the same antigens. (B) Sensitized mice
subsequently treated with OVA or HDM under the cover of anti-CD4 showed protection from AHR (n=8 for OVA, n=6 to HDM). Data are
representative of two independent experiments. (C) Mice were initially sensitized with OVA-alum or b-LG-alum, and tolerized to the same or a
different antigen on days 50 and 64. All mice were challenged i.n. with the same antigen used for initial sensitization. (D) Mice treated with a different
antigen together with anti-CD4 did not show reduced BAL eosinophilia (OVA .tb-LG and b-LG .tOVA) while treatment with anti-CD4 and the same
antigen used for sensitization showed a significant reduction of BAL eosinophilia (OVA.tOVA and b-LG .tb-LG; n=6, *** P,0.001). Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0022320.g004
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effects can be achieved in chronic allergic airways disease.
Materials and Methods
Experimental animals
BALB/c mice were bred and maintained under specific
pathogen-free facilities. Animals were sensitized, at the times
described in the text, by i.p. injection of 20 mg in 2.0 mg of
endotoxin-free aluminum hydroxide (Alu-gel-S, Serva, Heidel-
berg, Germany) of OVA or b-LG (Sigma, St Louis, USA)
previously run through a DetoxyGel column (Pierce, Rockford,
USA), or HDM extract (Greer, Lenoir, USA). In all experiments
animals were age and sex matched.
Ethics Statement
All experiments involving animals were approved by Direccao
Geral Veterinaria (approval 018831). Mice were bred and
maintained under specific pathogen free (SPF) conditions.
Antibodies and reagents
Non-depleting anti-CD4 (YTS177) [18] and the isotype control
(YKIX302) MAbs were produced in our laboratory using Integra
CL1000 flasks (IBS, Chur, Switzerland), and purified from culture
supernatants by 50% ammonium sulfate precipitation, dialyzed
against PBS, and the purity checked by native and SDS gel
electrophoresis. The hybridomas were generously provided by
Professor Herman Waldmann (Oxford, UK).
Bronchoalveolar Lavage (BAL)
Airways were washed through the trachea with 3 ml of cold
PBS 1% BSA (Sigma). The BAL was centrifuged, ressuspended in
PBS, and the cells counted with a hemocytometer. Differential cell
counts were performed on cytospin samples stained with Giemsa-
Wright (Sigma). At least 200 cells from each sample were counted,
using blinded slides, to determine the relative frequency of each
cell type. In addition, in some experiments eosinophilia was
independently confirmed by flow cytometry using GR-1 (eBios-
ciences, San Diego, CA, USA), CCR3 (BD Pharmingen, San
Diego, USA), and MHC-class II MAbs (produced in-house), with
eosinophils identified based on the SSC/FSC profile and as the
GR1
intMHCclass II
2CCR3
+ cells [31].
Quantification of immunoglobulins and cytokines
Serum titers of OVA-specific IgG1, IgG2a, and IgE were
measured by ELISA using the following: IgG1 and IgG2a (South-
ernBiotech, Birmingham, USA) with anti-OVA IgG1 standard from
Serotec, Oxford, UK; IgE (BD-Pharmingen) with anti-OVA IgE
standard from Abcam (Cambridge, UK). Cytokine titers were
determined in fresh BAL and lung homogenates. Cytokine ELISAs
wereperformedusingthefollowingkits:IL-4,IL-5(BD-Pharmingen).
Histology
Lungs wereperfusedwith4%formalinsolution(Sigma),collected
and sectioned. Staining was performed using hematoxilin/eosin,
and periodic acid-Schiff (PAS) stain. Photographs were taken using
a Leica DM2500 microscope and a Leica DFC420 camera.
Respiratory mechanics and methacholine responsiveness
Airway responsiveness was determined 24 hours after last
intranasal OVA challenge. Changes in the respiratory input
impedance (Zrs) were measured using a modification of the low
frequency forced-oscillation technique (LFOT) in mice anesthe-
tized with 10 ml/g of xylazine (2 mg/ml, Ronpum, Bayer,
Germany) and ketamine (40 mg/ml, Merial, Lyon, France),
tracheostomized and ventilated (FlexiVent, SciReq, Montreal,
Canada). Mice were hyperventilated at 450 breaths/min and Zrs
was measured during periods of apnea using a 16 s signal
containing 19 prime sinusoidal frequencies as described else-
where [32]. Calculation of airway resistance (Raw), tissue
damping (G) and tissue elastance (H) is obtained from the Zrs
spectrum using FlexiVent software (SciReq). AHR was measured
by exposure to an aerosol containing increasing doses of MCh
(Sigma), following a baseline measurement after the delivery of a
saline aerosol.
Statistical analysis
Statistical significance was determined using the two-tailed non-
parametric Mann-Whitney test and P values ,0.05 were deemed
significant (*, P,0.05; **, P,0.01; ***, P,0.001).
Supporting Information
Figure S1 Prevention of allergic sensitization with
anti-CD4 MAbs. Female BALB/c mice were sensitized with
20 mg OVA-alum i.p. and challenged with 50 mg OVA in saline
i.n. on the indicated days. Some animals were treated with 1 mg
anti-CD4 or an isotype control i.p. as shown. Naive mice, not
subjected to any intervention, were also studied as a control group
and compared with mice injected with adjuvant in the absence of
antigen at the time of sensitization. (A) Cellular composition of the
BAL of mice treated with anti-CD4 at the time of sensitization. (B)
Cellular composition of the BAL of mice treated with anti-CD4 at
the time of initial sensitization, but subjected to additional
sensitization at a subsequent time. (C) Cellular composition of
the BAL of sensitized mice treated with anti-CD4.
(TIF)
Figure S2 Invasive measurement of respiratory
mechanics. Data showing the impact of anti-CD4 treatment in
tissue elastance and tissue damping in response to increasing doses
of inhaled MCh. These graphs complement the data on airway
resistance represented in the main figures 1 to 5.
(TIF)
Figure S3 Induction of AHR following i.n. exposure
to the antigen. Female BALB/c mice were sensitized with two
shots of 20 mg OVA-alum i.p. 14 days apart, and challenged with
50 mg OVA in saline i.n. for three consecutive days (day 20–22), or
just on day 20. Invasive measurement of respiratory mechanics
was performed on the following day in presence of increasing
doses of inhaled Mch. Both groups of mice, subjected to a single or
three challenges with i.n. antigen, displayed similar levels of AHR
(n=6, ** P,0.01, *** P,0.001).
(TIF)
Figure S4 Allergic airways disease in mice with different
age. Female BALB/c mice were sensitized with 20 mg OVA-alum
i.p. and challenged with 50 mg OVA in saline i.n. as indicated in
Figure 1. Some animals were treated with 1 mg anti-CD4 or an
isotype control i.p. at the time of sensitization. Mice with 11 or 20
weeks of age were used. No significant differences between mice of
different ages.
(TIF)
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